International

Asia Pacific

Trinity has been working in the APAC region for over 10 years and has completed over 550 projects related to the region. There are ~20 Trinity experts associated with the Asia Pacific Center of Excellence.

Home / International / Asia Pacific

Trinity supports global and local clients with commercialization strategies in the APAC region, in addition to supporting local clients with global expansion strategies.

We leverage our expertise of APAC markets to develop recommendations and strategies pertinent to local needs.
We bring APAC-specific and evidence-based insights to support our recommendations.
We enhance communication and collaboration across global and APAC teams to ensure local needs are addressed.

Supporting All Commercialization Needs
Corporate & New Product Strategy
- Corporate Strategy
- Business Development
- New Product Planning
Launch & Brand Excellence
- Launch Planning
- Brand Planning
- Strategic Competitive Intelligence
Evidence, Value, Access & Pricing
- Evidence Strategy
- Value, Access & Pricing
Primary & Secondary Insights
- Qualitative and Quantitative Research
Analytics
- Forecasting
Questions We Can Help You Answer
What is our China go-to-market strategy?
- Should we target Tier 1 vs other Tier cities? How should we approach reaching the rural segment?
- How should we consider partnerships / joint ventures with local companies?
- What accelerated commercialization options can I leverage (e.g., Free Trade Zones, breakthrough therapy)?
How should we be organized across different APAC markets?
- What business model would ensure optimal collaboration between global/HQ teams and local affiliates?
- What business model would I need for APAC? Are there ‘archetypes’ across regions?
- How should we invest/partner with local/regional R&D hubs (e.g., China, Singapore)?
- What commercial capabilities do we need to build to remain competitive in the future?
How do we ensure pricing and market access success?
- Is national reimbursement in China still the ‘best option’? How sustainable is a private insurance / cash-pay model?
- What price can we expect in local markets? How should we consider local/regional price referencing?
- What innovative access and reimbursement options could we explore (e.g., hospital reimbursement pathway, Nanbayu, pay-by-installments)
How do I maximize value in local markets?
- What are opportunities to optimize our portfolio to meet local needs (e.g., medical, economic)?
- How should we accelerate global development programs to meet specific needs in APAC?
- What local innovation and business development opportunities should we pursue?
Unique regional capabilities
- Multilingual experts that are fluent in local language (Chinese, Japanese, Korean, etc.) to ensure optimal execution of research programs
- Extensive network of stakeholder types, including KOLs, providers, regulatory experts, payers and patients
- Ability to conduct market research in different formats (in-person, telephone, video platform, central facility, web survey)

Latest Asia Pacific Intelligence

Blog

NRDL 2024: Rare Diseases Deep Dive

China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation. The National […]

Webinars

The NRDL Conundrum: Balancing Between Access and Pricing for Innovation

Available On Demand

What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.

Watch Now

White Papers

2023 NRDL Pricing Implementation and Market Access Outcomes Update

The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.

View All APAC Thought Leadership